<DOC>
	<DOCNO>NCT02419508</DOCNO>
	<brief_summary>The purpose study evaluate additive intraocular pressure ( IOP ) lower effect brinzolamide 1 % /brimonidine 0.2 % ( dosed twice per day ( BID ) ) add PGA patient open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>SIMBRINZA速 Suspension BID Adjunctive Prostaglandin Analogue ( PGA )</brief_title>
	<detailed_description>This study consist 2 sequential phase : Screening/Eligibility Phase , include Run-in/Washout ( Phase I ) , Masked Treatment Phase ( Phase II ) . At Screening Visit , subject assign one 3 PGA therapy group duration study . Subjects previously prescribe TRAVATAN速 , XALATAN速 , LUMIGAN速 monotherapy uncontrolled IOP need run-in period PGA .</detailed_description>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis either openangle glaucoma ocular hypertension ; Must sign inform consent form ; Willing able attend study visit ; Other protocolspecified inclusion criterion may apply . Women childbearing potential pregnant , breastfeeding , intend become pregnant study , use adequate birth control method prevent pregnancy throughout study ; Any form glaucoma openangle glaucoma ocular hypertension ; Ocular disease , trauma , infection , inflammation , pathology , surgery specify protocol ; Any condition include severe illness would make subject , opinion Investigator , unsuitable study ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>